EuMentis Therapeutics

Developing Novel Drugs to Treat Neurodevelopmental and Neurodegenerative Conditions

  • Stage Product In Development
  • Industry Biotechnology
  • Location Newton, MA, USA
  • Currency USD
  • Founded April 2019
  • Employees 5
  • Incorporation Type C-corp
  • Website TBD

Company Summary

Eumentis is a development stage biotech focused on developing it's lead molecule EM-036, a 2nd-Gen NMDAR antagonist for the treatment of Autism-spectrum disorders and Alzheimer's Disease. The company is currently raising $3-5M in a seed round to complete IND enabling studies, file its IND, manufacture CTM and complete Phase I clinical trials. Exit will be trade sale or IPO upon reaching P2 clinical POC.

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free